NCT05095246View on ClinicalTrials.gov

A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 8, 2022

Primary Completion Date

July 1, 2024

Study Completion Date

October 30, 2024

Conditions
Cystic Fibrosis
Interventions
BIOLOGICAL

KB407 (Nebulization)

Nebulized solution of KB407, a replication-incompetent HSV-1 expressing full length human CFTR

Trial Locations (1)

2305

Hunter Medical Research Institute, Newcastle

Sponsors
All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

Krystal Biotech, Inc.

INDUSTRY

NCT05095246 - A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis | Biotech Hunter | Biotech Hunter